Recent 8-K filings for SYRE

• May 29, 2026, 4:45 PM ET other material materiality 0.30 neutral item 5.02item 5.07item 9.01

  Spyre Therapeutics stockholders approve amended ESPP; director Peter Harwin resigns

  Stockholders approved amended and restated 2016 ESPP (66.9M for, 45.5K against) at May 27 annual meeting.

• May 5, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Spyre Q1 net loss $69M; SPY001 hits primary endpoint; cash runway to H2 2029

  Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025; R&D expenses $60.4M (up from $41.6M).

• April 16, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Spyre Therapeutics raises ~$463.5M in underwritten public offering of 7.475M shares at $62.00/share

  Gross proceeds of ~$463.5M from 7.475M shares including full exercise of over-allotment option at $62.00/share.

• April 13, 2026, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Spyre SPY001 meets primary endpoint in Phase 2 SKYLINE Part A for UC; 40% clinical remission

  SPY001 achieved primary endpoint with RHI reduction of 9.2 points (p<0.0001) at Week 12.

• April 13, 2026, 7:59 PM ET other material materiality 0.70 positive item 2.02item 8.01

  Spyre reports preliminary $741M cash; suspends ATM offering

  Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.

• February 19, 2026, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Spyre Therapeutics reports Q4 2025 net loss of $62.5M; cash $756.5M; Phase 2 readouts expected Q2/Q4 2026

  Q4 2025 net loss $62.5M (vs $56.3M Q4 2024); R&D expense $44.6M (vs $50.5M).

• January 12, 2026, 6:59 PM ET leadership materiality 0.70 positive item 7.01item 9.01

  Spyre appoints CCO, accelerates SPY001 readout to Q2; six proof-of-concept reads expected in 2026

  Appointed Kate Tansey Chevlen as CCO; previously Amgen VP, Global Marketing Head for Immunology.

• November 4, 2025, 6:59 PM ET other material materiality 0.85 positive item 2.02item 7.01item 8.01item 9.01

  Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M

  SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.

• October 15, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 9.01

  Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50

  Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.

• October 14, 2025, 7:59 PM ET other material materiality 0.50 neutral item 2.02

  Spyre Therapeutics expects $486.2M cash as of Sept 30, 2025

  Preliminary unaudited cash, cash equivalents and marketable securities of ~$486.2M as of Sept 30, 2025.

• August 5, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Spyre Q2 net loss $36.7M; cash $526.6M; initiates Phase 2 SKYLINE-UC; TL1A data positive

  Net loss of $36.7M for Q2 2025 ($38.8M in Q2 2024); stock-based compensation $9.4M.

• June 17, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Spyre reports positive Phase 1 data for SPY002 & SPY072; half-life ~75 days, Phase 2 trials initiated

  SPY002 and SPY072 well tolerated up to 1500 mg; no serious AEs, no TEAEs >Grade 2, no discontinuations.

• June 2, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Spyre Therapeutics stockholders elect three Class III directors at 2025 annual meeting

  Elected Peter Harwin (38.2M for, 8.0M withheld), Michael Henderson (45.4M for, 0.7M withheld), Sandra Milligan (37.6M for, 8.6M withheld) as Class III directors.

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Spyre Therapeutics Q1 net loss $44.8M; cash $564.8M; on track for Phase 2 starts mid-2025

  Cash, cash equivalents, and marketable securities of $564.8M as of March 31, 2025.

• March 6, 2025, 6:59 PM ET other material materiality 0.75 negative item 4.01item 9.01

  Spyre dismisses PwC as auditor, appoints KPMG; discloses material weakness in controls

  PwC dismissed as auditor effective Feb 28, 2025; KPMG appointed as new independent auditor for FY2025.

• February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Spyre reports Q4 2024 net loss of $56.3M; cash $603M; pipeline on track with Phase 2 trials in 2025

  Cash, cash equivalents, and marketable securities $603.1M as of Dec 31, 2024; cash runway into H2 2028.

• January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02item 8.01item 9.01

  Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028

  Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.

• November 19, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01

  Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50

  Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.

• November 18, 2024, 6:59 PM ET other material materiality 0.85 negative item 4.02item 8.01

  Spyre Therapeutics restates net loss per share from 2023-2024; material weakness in controls

  Restating audited and unaudited financials from Dec 31, 2023 to Sep 30, 2024 due to misapplication of GAAP in EPS calculation for preferred stock.

• November 12, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Spyre reports positive Phase 1 data for SPY001; half-life >90 days, supports Q3M-Q6M dosing

  SPY001 half-life >90 days (300mg SC) and >100 days (600mg SC), ~4-fold greater than vedolizumab's 25-day half-life.

• November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Spyre Therapeutics reports Q3 net loss of $69M; pipeline on track with SPY001 Phase 1 data by year-end

  Net loss of $69.0M in Q3 2024 (vs $40.1M in Q3 2023); R&D expenses rose to $44.7M from $24.7M.

• October 15, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 8.01item 9.01

  Spyre accelerates SPY003 (IL-23) to first-in-human Q1 2025; licenses from Paragon for up to $22M

  First-in-human dosing of SPY003 (anti-IL-23) now expected Q1 2025; interim data expected H2 2025.

• August 8, 2024, 7:59 PM ET other material materiality 0.00 neutral

  Spyre Therapeutics files 8-K/A to correct date on cover page of prior filing

  Amendment corrects clerical error on cover page date of Original 8-K filed August 7, 2024.

• August 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end

  Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.

• May 30, 2024, 7:59 PM ET other materiality 0.30 neutral item 7.01

  Spyre Therapeutics updates share count: 50.8M actual, 65.3M pro forma

  As of May 29, 2024, common shares outstanding: 50,782,384.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

11 positive 2 negative 12 neutral

source · SYRE on sec.gov